Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313351360> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4313351360 endingPage "132.41" @default.
- W4313351360 startingPage "132.41" @default.
- W4313351360 abstract "Abstract Natural Killer T cells (NKT) initiate potent anti-tumor responses upon activation by glycolipid antigens presented by CD1d, a non-classical MHC class I-like antigen presenting molecule. Anti-tumor responses are induced following NKT cell activation through their direct production of cytokines such as IFN-γ, and through a variety of indirect effects including dendritic cell maturation, the activation of NK cells and the cross-priming of tumor-specific CD8+ T cells. The glycolipid α-galactosylceramide (α-GC) is a CD1d ligand and potent NKT cell activator that enhances anti-tumor immune responses and decreases metastases in vivo. However, the response is short-lived, and causes liver toxicity and long term anergy of NKT cells. Here we report a novel class of chemically modified α-GCs, designated GCBs, that demonstrate unique binding properties to both mouse and human CD1d and enhanced NKT cell stimulation in vitro, as compared to previously described NKT cell activating ligands. A range of analyses have been carried out to characterize the structure and stability of GCB:CD1d complexes, revealing unique features that distinguish them from previously analyzed α-GC:CD1d complexes. Soluble GCB:CD1d complexes are currently being tested in vivo in mouse models for their ability to drive the sustained activation of NKT cells, which may provide a superior approach for development of improved cancer immunotherapies." @default.
- W4313351360 created "2023-01-06" @default.
- W4313351360 creator A5011149577 @default.
- W4313351360 creator A5016158429 @default.
- W4313351360 creator A5058424034 @default.
- W4313351360 creator A5064497507 @default.
- W4313351360 creator A5070783372 @default.
- W4313351360 creator A5071971878 @default.
- W4313351360 creator A5076358930 @default.
- W4313351360 date "2013-05-01" @default.
- W4313351360 modified "2023-09-27" @default.
- W4313351360 title "α-Galactosylceramide analogues in cancer immunotherapeutics (P2102)" @default.
- W4313351360 doi "https://doi.org/10.4049/jimmunol.190.supp.132.41" @default.
- W4313351360 hasPublicationYear "2013" @default.
- W4313351360 type Work @default.
- W4313351360 citedByCount "0" @default.
- W4313351360 crossrefType "journal-article" @default.
- W4313351360 hasAuthorship W4313351360A5011149577 @default.
- W4313351360 hasAuthorship W4313351360A5016158429 @default.
- W4313351360 hasAuthorship W4313351360A5058424034 @default.
- W4313351360 hasAuthorship W4313351360A5064497507 @default.
- W4313351360 hasAuthorship W4313351360A5070783372 @default.
- W4313351360 hasAuthorship W4313351360A5071971878 @default.
- W4313351360 hasAuthorship W4313351360A5076358930 @default.
- W4313351360 hasConcept C100701293 @default.
- W4313351360 hasConcept C139563560 @default.
- W4313351360 hasConcept C147483822 @default.
- W4313351360 hasConcept C154317977 @default.
- W4313351360 hasConcept C167672396 @default.
- W4313351360 hasConcept C170627219 @default.
- W4313351360 hasConcept C202751555 @default.
- W4313351360 hasConcept C203014093 @default.
- W4313351360 hasConcept C2776090121 @default.
- W4313351360 hasConcept C2778607024 @default.
- W4313351360 hasConcept C37386791 @default.
- W4313351360 hasConcept C502942594 @default.
- W4313351360 hasConcept C55493867 @default.
- W4313351360 hasConcept C59822182 @default.
- W4313351360 hasConcept C81444415 @default.
- W4313351360 hasConcept C86803240 @default.
- W4313351360 hasConcept C8891405 @default.
- W4313351360 hasConcept C95444343 @default.
- W4313351360 hasConceptScore W4313351360C100701293 @default.
- W4313351360 hasConceptScore W4313351360C139563560 @default.
- W4313351360 hasConceptScore W4313351360C147483822 @default.
- W4313351360 hasConceptScore W4313351360C154317977 @default.
- W4313351360 hasConceptScore W4313351360C167672396 @default.
- W4313351360 hasConceptScore W4313351360C170627219 @default.
- W4313351360 hasConceptScore W4313351360C202751555 @default.
- W4313351360 hasConceptScore W4313351360C203014093 @default.
- W4313351360 hasConceptScore W4313351360C2776090121 @default.
- W4313351360 hasConceptScore W4313351360C2778607024 @default.
- W4313351360 hasConceptScore W4313351360C37386791 @default.
- W4313351360 hasConceptScore W4313351360C502942594 @default.
- W4313351360 hasConceptScore W4313351360C55493867 @default.
- W4313351360 hasConceptScore W4313351360C59822182 @default.
- W4313351360 hasConceptScore W4313351360C81444415 @default.
- W4313351360 hasConceptScore W4313351360C86803240 @default.
- W4313351360 hasConceptScore W4313351360C8891405 @default.
- W4313351360 hasConceptScore W4313351360C95444343 @default.
- W4313351360 hasIssue "1_Supplement" @default.
- W4313351360 hasLocation W43133513601 @default.
- W4313351360 hasOpenAccess W4313351360 @default.
- W4313351360 hasPrimaryLocation W43133513601 @default.
- W4313351360 hasRelatedWork W1570691765 @default.
- W4313351360 hasRelatedWork W1578871315 @default.
- W4313351360 hasRelatedWork W1808459640 @default.
- W4313351360 hasRelatedWork W2034406338 @default.
- W4313351360 hasRelatedWork W2070061961 @default.
- W4313351360 hasRelatedWork W2079835268 @default.
- W4313351360 hasRelatedWork W2087244840 @default.
- W4313351360 hasRelatedWork W2093116728 @default.
- W4313351360 hasRelatedWork W2104085064 @default.
- W4313351360 hasRelatedWork W2117515390 @default.
- W4313351360 hasVolume "190" @default.
- W4313351360 isParatext "false" @default.
- W4313351360 isRetracted "false" @default.
- W4313351360 workType "article" @default.